US SEC Trading Suspension Halt Orders — May 22, 2026

22-05-2026

All In FutureTech Alliance, Inc. (formerly Allied Gaming & Entertainment Inc., Nasdaq: AGAE) received a Nasdaq deficiency letter on May 19, 2026, for failing to timely file its Q1 2026 Form 10-Q and remaining delinquent on its FY2025 Form 10-K, creating an additional basis for potential delisting. However, the company announced on May 21, 2026, that it has now filed its FY2025 Annual Report and is working to file the Q1 2026 Form 10-Q, while the delisting notice has no immediate effect on trading. The company is pursuing a strategic transformation into an AI-focused digital infrastructure platform, but the filing delays and Nasdaq non-compliance represent significant ongoing risks.

• · The company received the Nasdaq deficiency letter on May 19, 2026, for failing to file its Q1 2026 Form 10-Q by the due date of May 15, 2026, and for remaining delinquent on its FY2025 Form 10-K.
• · The company filed its FY2025 Annual Report on Form 10-K on May 22, 2026, the same day as this 8-K filing.
• · The Q1 2026 Form 10-Q is still in preparation and has not yet been filed.
• · The company will continue to communicate with the Nasdaq Hearings Panel as part of an existing hearing process.
• · The company is undergoing a strategic transformation from a global experiential entertainment business into an AI-focused digital infrastructure platform.
• · Chairman and CEO James Li stated that major litigation disputes that had impeded development over the past two years have been resolved.
• · The company's common stock trades under the symbol AGAE on Nasdaq.

22-05-2026

TransCode Therapeutics, Inc. (RNAZ) received a Nasdaq deficiency letter on May 19, 2026, for failing to meet the minimum stockholders' equity requirement of $2,500,000, reporting only $1,251,427 in its March 31, 2026 10-Q. The company has until July 3, 2026, to submit a compliance plan, and may receive up to a 180-day extension, but faces significant risk of delisting if unable to regain compliance, which would materially adversely affect its operations and share value.

• · The deficiency letter was received on May 19, 2026, and the 8-K was filed on May 22, 2026.
• · The company has 45 calendar days (until July 3, 2026) to submit a compliance plan to Nasdaq.
• · If the compliance plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the deficiency letter to regain compliance.
• · If the plan is rejected or compliance is not achieved, the company may appeal to a Nasdaq Hearings Panel, which would stay any delisting action.
• · The company's common stock trades under the symbol RNAZ on the Nasdaq Capital Market.

22-05-2026

RCI Hospitality Holdings, Inc. received a Nasdaq notice on May 20, 2026, for non-compliance with Listing Rule 5250(c)(1) due to the delayed filing of its Form 10-Q for the quarter ended March 31, 2026. The company has until July 20, 2026, to submit a compliance plan, and if accepted, Nasdaq may grant an exception until November 16, 2026, to regain compliance. The notice has no immediate effect on the listing of RICK common stock on the Nasdaq Global Market.

• · The company must submit a compliance plan by July 20, 2026, or face potential delisting.
• · If Nasdaq accepts the plan, an exception of up to 180 calendar days (until November 16, 2026) may be granted.
• · The delayed filing is the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

22-05-2026

Terra Innovatum Global N.V. (NKLR) received a deficiency notice from Nasdaq on May 19, 2026, for failing to timely file its Form 10-Q for the quarter ended March 31, 2026, and remaining delinquent on its Form 10-K for the fiscal year ended December 31, 2025, violating Nasdaq Listing Rule 5250(c)(1). The notice has no immediate effect on trading, and the company has until June 15, 2026, to submit a compliance plan; if accepted, Nasdaq may grant an exception until October 12, 2026. The company intends to regain compliance as soon as practicable, but the filing delays represent a material risk to continued listing.

• · The company has until June 15, 2026, to submit a plan to regain compliance.
• · If Nasdaq accepts the plan, an exception of up to 180 calendar days from the due date of the Form 10-K (as extended) may be granted, until October 12, 2026.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
• · The company's ordinary shares (par value €0.01 per share) trade on the Nasdaq Global Select Market under the symbol NKLR.

22-05-2026

Ensysce Biosciences received a delisting notice from Nasdaq on May 21, 2026, due to non-compliance with the $2.5 million stockholders' equity requirement as of March 31, 2026. The company has 45 days (until July 6, 2026) to submit a compliance plan; if accepted, it may receive up to 180 days to regain compliance. However, there is no assurance that Nasdaq will accept the plan or that the company will ultimately regain compliance.

• · The delisting notice was received on May 21, 2026, and the filing was made on May 22, 2026.
• · The company may appeal to the Nasdaq Hearings Panel if the compliance plan is not accepted.
• · The company intends to actively explore options to regain compliance, but no specific actions or financial details were disclosed.

22-05-2026

Atlantic American Corporation received a Nasdaq notice on May 21, 2026, for non-compliance with Listing Rule 5250(c)(1) due to delinquent filing of its Form 10-K for FY2025 and Form 10-Q for Q1 2026. The company has until June 16, 2026, to submit a compliance plan; if accepted, Nasdaq may grant an extension until October 12, 2026. The notice has no immediate effect on the listing of AAME common stock on the Nasdaq Global Market.

• · The company remains delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the period ended March 31, 2026.
• · If Nasdaq accepts the compliance plan, the company may be granted up to 180 calendar days from the prescribed due date for the Form 10-K (i.e., until October 12, 2026) to regain compliance.
• · If the plan is not accepted, the company has the opportunity to appeal to a Nasdaq Hearings Panel.
• · The company issued a press release on May 22, 2026, announcing receipt of the notice.

22-05-2026

On May 21, 2026, Tenon Medical, Inc. received a Nasdaq notice of non-compliance with the minimum stockholders' equity requirement of $2.5 million, after reporting stockholders' equity of only $1,895,000 in its March 31, 2026 Form 10-Q. The company has 45 days (until July 6, 2026) to submit a compliance plan, and if accepted, may receive up to 180 days to regain compliance. There is no immediate impact on trading, but failure to regain compliance could lead to delisting.

• · The company does not currently meet alternative compliance standards related to market value of listed securities or net income from continuing operations.
• · If Nasdaq rejects the compliance plan or delisting is initiated, the company may appeal to a Nasdaq Hearings Panel, which would stay any suspension/delisting pending the hearing process and any additional extension granted by the panel.
• · The Notice has no immediate effect on the listing or trading of the company's common stock (TNON) or warrants (TNONW) on the Nasdaq Capital Market.
• · The company has not elected to use the extended transition period for complying with new or revised financial accounting standards (as an emerging growth company).

22-05-2026

On May 21, 2026, SEGG Media Corporation (formerly Lottery.com Inc.) received a Nasdaq notice for failure to timely file its Form 10-Q for the period ended March 31, 2026, violating Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and may receive up to 180 days extension. The notice has no immediate effect on listing, but the company faces potential delisting risk.

• · The company's common stock trades under ticker SEGG on Nasdaq.
• · Warrants trade under ticker LTRYW with an exercise price of $2,300.00 per share.
• · The company is an emerging growth company and has not elected to use extended transition period for new accounting standards.

22-05-2026

Global Interactive Technologies, Inc. (GITS) received a Nasdaq delinquency notice on May 21, 2026, for failing to timely file its Q1 2026 10-Q, adding to a prior delinquency for its FY2025 10-K. The company now faces a maximum 180-day cure period ending October 12, 2026, and must submit an updated compliance plan by June 22, 2026. The repeated filing failures and compressed timeline heighten delisting risk.

• · The company's FY2025 10-K remains unfiled as of the Notice date.
• · The company must submit an updated compliance plan to Nasdaq by June 22, 2026.
• · The maximum cure period for all delinquent filings is 180 calendar days from the due date of the initial delinquent filing, ending October 12, 2026.

22-05-2026

Laser Photonics Corp received a Nasdaq deficiency notice on May 21, 2026, for failing to file its Form 10-Q for the period ended March 31, 2026, violating continued listing rules. The company has 60 days to submit a compliance plan, with a possible extension until November 16, 2026. This filing highlights a significant compliance risk that could lead to delisting if not resolved.

• · The deficiency notice was received on May 21, 2026.
• · The company has until November 16, 2026, at the latest to regain compliance if an extension is granted.
• · A press release regarding the deficiency notice was issued on May 22, 2026, and is attached as Exhibit 99.1.

22-05-2026

Tempest Therapeutics received a Nasdaq deficiency letter on May 19, 2026 for failing to meet the minimum stockholders' equity requirement of $2.5M, reporting only $822,000 as of March 31, 2026. Additionally, on May 22, 2026, the company notified Nasdaq of non-compliance with independent director and committee requirements due to board resignations. The company has 45 days to submit compliance plans, but faces significant risk of delisting if unable to regain compliance.

• · Company has 45 calendar days (until July 6, 2026) to submit a plan to regain compliance with stockholders' equity requirement.
• · If plan accepted, Nasdaq may grant up to 180 calendar days extension to regain compliance.
• · Company also failed alternative quantitative standards: market value of listed securities ($35M) and net income from continued operations ($500,000).
• · Board resignations caused non-compliance with majority independent director, audit committee, compensation committee, and nominating committee requirements.
• · Company is not eligible for cure period for independent director requirements due to more than one vacancy.
• · Company must submit compliance plan for independent director requirements within 45 calendar days.
• · Common stock continues to trade under symbol TPST on Nasdaq Capital Market with no immediate effect on listing.

22-05-2026

La Rosa Holdings Corp. (LRHC) received a Nasdaq deficiency notice on May 21, 2026, for failing to timely file its Form 10-Q for Q1 2026 and remaining delinquent on its Form 10-K for FY2025, violating Listing Rule 5250(c)(1). The company has until June 15, 2026, to submit a compliance plan)Skip and Nasdaq may grant an extension until October 12, 2026. While the notice has no immediate effect on listing, there is no assurance the company will regain compliance, and the stock continues to trade under 'LRHC' on The Nasdaq Capital Market.

• · The company is also delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2025.
• · The company has until June 15, 2026, to submit a plan of compliance to Nasdaq.
• · Nasdaq may grant an extension of up to 180 calendar days from the Form 10-K's due date, or until October 12, 2026, to regain compliance.
• · The company expects to file the delinquent reports and/or submit the compliance plan by June 15, 2026, but there is no assurance of success.
• · The company issued a press release on May 22, 2026, as required by Nasdaq Listing Rule 5810(b).

22-05-2026

Anavex Life Sciences Corp. received a Nasdaq delinquency notice on May 20, 2026, for failing to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, violating Listing Rule 5250(c)(1). The company has until July 20, 2026, to submit a compliance plan, with a possible extension to November 16, 2026. While the stock continues to trade on Nasdaq under 'AVXL', the notice introduces regulatory risk and potential delisting if compliance is not regained.

• · The company has until July 20, 2026, to submit a plan to regain compliance.
• · If Nasdaq accepts the plan, an exception of up to 180 calendar days from the Form 10-Q's due date (until November 16, 2026) may be granted.
• · If the compliance plan is not accepted, the company can appeal to a Nasdaq Hearings Panel.
• · The company is working to complete and file the Form 10-Q and submit a compliance plan.

22-05-2026

GT Biopharma received a Nasdaq letter granting an additional 180-day compliance period until November 16, 2026, to meet the $1.00 minimum bid price requirement. The company previously failed to regain compliance during the initial period ending May 19, 2026. There is no assurance of regaining compliance.

• · Initial compliance period ended May 19, 2026, without regaining compliance.
• · Company meets all other listing requirements except bid price.
• · To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.

22-05-2026

DevvStream Corp. (DEVS) received a formal notification on May 20, 2026, that it has not regained compliance with Nasdaq's minimum $500,000 net income requirement (Listing Rule 5550(b)) after the expiration of its compliance extension on May 18, 2026. The company also faces a separate bid price deficiency (closing below $1.00 per share for 30 consecutive business days) and is ineligible for a compliance period due to a prior reverse stock split. A Nasdaq hearings panel will consider both deficiencies in deciding whether to delist the company's common shares, and DevvStream intends to submit its views by May 27, 2026, but there is no assurance of regaining compliance or maintaining its listing.

• · The company previously received a net income deficiency notice on November 18, 2025, and was granted a compliance extension until May 18, 2026.
• · A separate bid price deficiency notice was received on April 7, 2026, covering the period February 23, 2026 to April 6, 2026.
• · The company is ineligible for a compliance period for the bid price rule because it effected a reverse stock split within the prior one-year period.
• · A hearing before the Nasdaq Hearings Panel occurred on May 19, 2025 (likely a typo for 2026) to address the bid price deficiency.
• · The company must present its views on the net income deficiency to the Panel in writing by May 27, 2026.

22-05-2026

Envoy Medical (COCHW) received a second staff notification from Nasdaq on May 19, 2026, granting a 180-day extension (until November 16, 2026) to regain compliance with the $1.00 minimum bid price requirement after failing to meet it by the original May 18, 2026 deadline. The company intends to potentially effect a reverse stock split to cure the deficiency, though it acknowledges risks related to unpredictable market prices and the effectiveness of such a measure.

• · Initial deficiency notice was received on November 19, 2025, due to failure to maintain minimum $1.00 bid price for 30 consecutive business days.
• · The company meets all other continued listing requirements for the Capital Market except the bid price requirement.
• · The company intends to potentially effect a reverse stock split to cure the deficiency during the second compliance period.
• · Forward-looking statements highlight risks including unpredictable market trade prices and potential diversion of management attention.